✦ LIBER ✦

A Phase II Feasibility Trial of Dose-Dense Docetaxel Followed by Doxorubicin/Cyclophosphamide as Adjuvant or Neoadjuvant Treatment for Women with Node-Positive or High-Risk Node-Negative Breast Cancer

✍ Scribed by Denise A. Yardley; Howard A. Burris III; Cindy P. Farley; John H. Barton; Nancy W. Peacock; David R. Spigel; F. Anthony Greco; John D. Hainsworth

Book ID: 119934797
Publisher: CIG Media Group, LP.
Year: 2008
Tongue: English
Weight: 109 KB
Volume: 8
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2008.n.027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized feasibility/phase II study

A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

✍ S. Margolin; L. Carlsson; M. Hellstrom; P. Karlsson; E. Lidbrink; B. Linderholm; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Cardiac safety results from a phase II,

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

✍ Hurvitz, Sara A; Bosserman, Linda D; Chan, David; Hagenstad, Christopher T; Kass 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 225 KB